Physician profile
Kelvin Hamner
NPI 1073656344
$8,024.92
in general payments reported to CMS, 2019-2025
30 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $753 · 2021: $1,239 · 2022: $1,230 · 2023: $926 · 2024: $1,289 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,734.16 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $1,254.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,032.69 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Gilead Sciences, INC. | $791.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.42 | 2019-2025 | Jardiance, Synjardy |
| Viiv Healthcare Company | $441.73 | 2022-2025 | Apretude |
| Sanofi-Aventis U.S. LLC | $342.46 | 2019-2022 | |
| Novo Nordisk INC | $302.92 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $290.65 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $196.02 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $190.05 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $143.15 | 2021-2023 | |
| Exact Sciences Corporation | $130.97 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $128.58 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $117.65 | 2019-2023 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116.03 | 2023-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $72.96 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $43.07 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.76 | 2023 | |
| Glaxosmithkline, LLC. | $23.60 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.54 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $21.84 | 2025 | Gemtesa |
| Allergan, INC. | $19.77 | 2019 | |
| Insulet Corporation | $19.48 | 2024 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $19.06 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.01 | 2025 | Uptravi, Opsumit |
| Hikma Pharmaceuticals USA | $17.23 | 2019 | |
| Linus Health, INC. | $14.71 | 2024 | Core Cognitive Evaluation |
| Medline Industries LP | $13.14 | 2020 | |
| Amarin Pharma, INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelvin Hamner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.